| Bioactivity | ACY-957 is an orally active and selective inhibitor of HDAC1 and HDAC2, with IC50s of 7 nM, 18 nM, and 1300 nM against HDAC1/2/3, respectively, and shows no inhibition on HDAC4/5/6/7/8/9[1]. | ||||||||||||
| Invitro | ACY-957 is a selective inhibitor of HDAC1 and HDAC2, with IC50s of 7 nM, 18 nM, and 1300 nM against HDAC1/2/3, respectively, and shows no inhibition on HDAC4/5/6/7/8/9. ACY-957 has an IC50 of 304 nM for HDAC2 in primary hematopoietic progenitors[1]. | ||||||||||||
| Name | ACY-957 | ||||||||||||
| CAS | 1609389-52-7 | ||||||||||||
| Formula | C24H23N5OS | ||||||||||||
| Molar Mass | 429.54 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Shearstone JR, et al. Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2. PLoS One. 2016 Apr 13;11(4):e0153767. |